$GH

Hidalgo Medina Manuel sold $130K of GH

Hidalgo Medina Manuel sold 1,000 shares of Guardant Health, Inc. (GH) at $130.06 ($0.13M total) on 2026-05-28.

Original reporting
SEC EDGAR · Hidalgo Medina Manuel
Published May 29, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 29, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The disclosure updates insider-trading visibility but does not provide new company performance, guidance, or deal information.

02

Market read

Traders may monitor GH for any follow-on insider activity, but the filing alone is unlikely to drive a major repricing.

03

What to watch

No 10b5-1 plan is cited; traders may want to check prior Form 4 cadence and whether sales cluster around specific events or option exercises.

Relevance 6/10Novelty 6/10Timing: Filed after-hours/late day (2026-05-29T17:30:38-04:00) following the 2026-05-28 sale.

Background

The article is an SEC Form 4 disclosure reporting an insider (director) transaction in Guardant Health shares.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Guardant Health director Hidalgo Medina Manuel filed a Form 4 open-market sale of 1,000 shares at ~$130.06 on 2026-05-28.

Expected impact

Low near-term impact; any reaction is likely limited unless part of a broader selling pattern.

Evidence & confidence

The filing is a director open-market sale with no 10b5-1 plan stated and no accompanying company-specific operational news.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

A single director open-market sale may reflect diversification or routine liquidity needs rather than negative fundamentals.

Key entities

  • Guardant Health, Inc.

    Publicly traded company whose director filed the Form 4 insider sale.

  • Hidalgo Medina Manuel

    Director who sold 1,000 GH shares at ~$130.06/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHMed

Guardant Health stock hits 52-week high at 176.68 USD

Guardant Health Inc. (GH) hit a 52-week high of $176.68, up 216.17% in a year. Q2 revenue grew 44% to $335M, beating expectations. Analysts raised price targets, with Stifel at $180 and TD Cowen at $210, both maintaining Buy ratings. Positive outlook driven by healthcare advancements and strong product performance.

$GHHighAI 9/10

Guardant Health (GH) Wins FDA Approval For First Liquid Biopsy In Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx, a liquid biopsy test to monitor ctDNA in advanced breast cancer. The test guides treatment decisions before disease progression, targeting about 37,000 eligible patients in the US. This approval may influence oncologist testing habits, payer coverage, and Guardant's competitive position in cancer diagnostics.

$GHHighAI 9/10

Guardant Health Announces Landmark FDA Approval of Guardant360® CDx as Companion Diagnostic for AstraZeneca’s ETCAMAH™ (camizestrant) in Advanced Breast Cancer

Guardant Health (GH) received FDA approval for Guardant360 CDx as a companion diagnostic for AstraZeneca's ETCAMAH in advanced breast cancer. The approval, based on the SERENA-6 trial, showed a 56% reduction in disease progression risk when using ctDNA-guided treatment. The test is recommended for use every three months during therapy.

$GHHighAI 9/10

Final judgement favours TwinStrand in Guardant patent case

TwinStrand Biosciences and the University of Washington won a patent infringement case against Guardant Health, with the court awarding $245.2M in damages and royalties. The judgement upholds a jury verdict that Guardant willfully infringed two patents and must pay a 6% royalty on relevant sales until 2033. The court also affirmed the validity of the patents in question.